89315-56-0

Usage

Uses

Used in Organic Synthesis:
5,7-Dichloro-1,2,3,4-tetrahydroisoquinoline is used as a building block in organic synthesis for the development of various compounds with potential biological activities. Its unique structure and the presence of chlorine atoms make it a versatile intermediate for creating a wide range of organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline is used as a key intermediate in the synthesis of new drugs. Its unique structure and functional groups contribute to the development of compounds with potential therapeutic applications, making it an important tool in medicinal chemistry.
Used in Materials Science:
5,7-Dichloro-1,2,3,4-tetrahydroisoquinoline may also have potential applications in the field of materials science. Its unique structure and properties could be utilized in the development of new materials with specific characteristics, such as improved stability or reactivity.
Used in Chemical Engineering:
In chemical engineering, 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline could be employed in the design and optimization of chemical processes, taking advantage of its unique properties and reactivity to improve the efficiency and selectivity of various chemical reactions.
Overall, 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline is a versatile chemical with diverse potential applications in various scientific and industrial fields, including organic synthesis, pharmaceutical research, materials science, and chemical engineering.

Upstream product

• 73075-58-8 5,7-dichloro isoquinoline 
• 1346177-18-1 C₉H₇Cl₂N 
• 6306-60-1 2,4-Dichlorophenylacetonitrile 
• 259796-12-8 3,5-dichloro-N-methoxy-N-methylbenzamide 
• 51-36-5 3,5-dichlorobenzoic acid 
• 52516-13-9 2-(2,4-dichloro-phenyl)-ethylamine 
• 34209-97-7 2,4-dichloro-1-(2-nitrovinyl)benzene 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 14046-52-7 N-(2-chloroethyl)-3,5-dichlorobenzylamine hydrochloride 
• 10203-08-4 3,5-dichlorobenzaldehyde 

Downstream Products

• 1289646-72-5 C₂₈H₂₃Cl₂N 
• 1194550-56-5 5,7-dichloro-2-trityl-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 
• 1194550-63-4 C₄₆H₄₀Cl₂N₂O₅S 
• 1194550-65-6 benzyl (S)-2-(5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-[3-(methylsulfonyl)phenyl]propanoate hydrochloride 
• 1194550-67-8 ((S)-benzyl 2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-methylsulfonyl)phenyl)propanoate 
• 1025967-78-5 (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid 
• 1289646-93-0 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid hydrochloride 
• 851784-82-2 2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid 

Relevant academic research and scientific papers

Preparation method of 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline

The invention provides a preparation method of 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline. The preparation method comprises the following steps: preparing a compound A by taking 3, 5-dichlorobenzoic acid as a raw material; preparing a compound B from the compound A; preparing a compound C from the compound B; preparing a compound D from the compound C; and obtaining a white solid 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline from the compound D. The preparation method of 5, 7-dichloro-1, 2, 3, 4-tetrahydroisoquinoline provided by the invention has the advantages of high product purity and high product yield.

Preparation method 5,7 - dichloro -1, 2, 3 and 4 - tetrahydroisoquinoline

The invention provides a preparation method of 5, 7 - dichloro -1, 2, 3 and 4 - tetrahydroisoquinoline, which comprises the following steps: reducing 2, 4 - dichlorobenzene acetonitrile by first reducing agent to generate 2 and 4 - dichlorophenylethylamin

Synthesis method of lifitegrast intermediate 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline

The invention discloses a synthesis method of a lifitegrast intermediate 5,7-dichloro-1,2,3,4-tetrahydroisoquinoline, wherein the synthesis method comprises the steps: by using 2,4-dichlorobenzaldehyde as a starting material, carrying out nitro-alcohol co

LFA-1 INHIBITOR AND POLYMORPH THEREOF

Methods of preparation and purification of a compound, intermediates thereof, a polymorph thereof, and related compounds are disclosed. Formulations and uses thereof in the treatment of LFA -1 mediated diseases are also disclosed.

Discovery and development of potent LFA-1/ICAM-1 antagonist SAR 1118 as an ophthalmic solution for treating dry eye

LFA-1/ICAM-1 interaction is essential in support of inflammatory and specific T-cell regulated immune responses by mediating cell adhesion, leukocyte extravasation, migration, antigen presentation, formation of immunological synapse, and augmentation of T-cell receptor signaling. The increase of ICAM-1 expression levels in conjunctival epithelial cells and acinar cells was observed in animal models and patients diagnosed with dry eye. Therefore, it has been hypothesized that small molecule LFA-1/ICAM-1 antagonists could be an effective topical treatment for dry eye. In this letter, we describe the discovery of a potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonist (SAR 1118) and its development as an ophthalmic solution for treating dry eye.

Inhibitors of phenylethanolamine N-methyltransferase and epinephrine biosynthesis: I. Chloro-substituted 1,2,3,4-tetrahydroisoquinolines

In a search for inhibitors of epinephrine biosynthesis as potential therapeutic agents, a series of 13 ring-chlorinated 1,2,3,4-tetrahydroisoquinolines was prepared. These compounds were tested initially for their ability to inhibit rabbit adrenal phenylethanolamine N-methyltransferase (PNMT) in vitro. Enzyme-inhibitor dissociation constants, determined for the six most potent members of the series, indicated the following order of decreasing potency: 7,8-Cl2>6,7,8-Cl3>7-Cl~8-Cl>5,6,7,8-Cl4>5,7,8-Cl3. These compounds were subsequently examined for PNMT-inhibiting activity in intact rats and mice. 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline (SK&F 64139) was the most potent member of the series both in vitro and in vivo and is currently undergoing clinical investigation.